



(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2024/059808

(22) International Filing Date:
12 December 2024 (12.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/609,644 13 December 2023 (13.12.2023) US

(71) Applicant: **PRETZEL THERAPEUTICS, INC.**
[US/US]; 1601 Trapelo Road, Suite 154, Waltham, Massachusetts 02451 (US).

(72) Inventors: **XIE, Xie**; c/o Pretzel Therapeutics, Inc., 1601 Trapelo Road, Suite 154, Waltham, Massachusetts 02451 (US). **SHI, Yonghong**; c/o Pretzel Therapeutics, Inc., 1601 Trapelo Road, Suite 154, Waltham, Massachusetts 02451 (US). **ZHU, Xuefeng**; c/o Pretzel Therapeutics, Inc., 1601 Trapelo Road, Suite 154, Waltham, Massachusetts 02451 (US).

(74) Agent: **DAUKSS, Dana M.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: OLIGONUCLEOTIDES TARGETING SAMHD1




FIG. 1

Oligo (SEQ ID NO)

(57) Abstract: Oligonucleotides and their use in modulating (e.g., inhibiting) SAMHD1 expression are provided. Compositions and pharmaceutical compositions comprising such oligonucleotides are also provided.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*